Ocata Therapeutics to be acquired by Astellas Pharma.
M2 EQUITYBITES-November 11, 2015-Ocata Therapeutics to be acquired by Astellas Pharma
(C)2015 M2 COMMUNICATIONS http://www.m2.com
Astellas Pharma, a Japan-based drug company, has agreed to acquire Ocata Therapeutics, a United States-based clinical stage biotechnology company, it was reported yesterday.
The deal is valued at USD379m. Astellas will make a tender offer worth USD8.50 a share in cash to buy Ocata.
Ocata develops and commercialises regenerative ophthalmology therapeutics. The company's principal R&D and commercial efforts relate to its Regenerative Ophthalmology programs and involves development of therapies to treat eye diseases and disorders. The transaction is intended to enable Astellas to establish a presence in ophthalmology and advance in the field of cell therapy.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 11, 2015|
|Previous Article:||Nicox signs license agreement with Fera Pharmaceuticals.|
|Next Article:||Morgan Stanley Income Securities announces monthly income dividend of USD0.045 per share.|